Seeking collaboration, licensing
ETH Zurich spin-out company, Cytos Biotechnology AG, is looking for partnerships to join their research and development of treatments for chronic diseases similar to the recently announced exclusive license agreement to develop a vaccine against nicotine addiction.
“Our business focuses on highly innovative research and development of a new class of medicines for chronic disease treatment and prevention. We aim to achieve proof-of-concept in man (e.g. phase II) for several vaccine candidates and thereafter advance them beyond clinical development to the market in collaboration with large pharmaceutical companies. With a hand-over of product candidates after proof-of-concept in phase II, we believe the strengths of both industries, small Biotech and big Pharma, are combined most effectively. Establishing such valuable partnerships will remain our goal for the next years,” said Dr. Claudine Blaser of Cytos Biotechnology AG.
Cytos Biotechnology has built a scientific network with several academic research institutions in the world. Through these contacts that involve grants funded by the Swiss Commission for Technology and Innovation (Kommission für Technologie und Innovation (KTI)) and European Union research collaborations as well as informal contacts, Cytos Biotechnology has prime access to cutting edge science, disease specific know-how, and additional specimens and research materials. Among the network partners of Cytos Biotechnology are:
Cytos Biotechnology was spun-out of the Swiss Federal
Institute of Technology (ETH) in